TBPH logo

THERAVANCE BIOPHARMA INC

TBPHNASDAQ
🏆 #2464 by market capUS Equity
$17.04▼ $0.01 (−0.03%)
Latest quote
🔔
Track TBPH
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.0%
7d—
14d—
30d▲ 0.0%
ytd▼ 8.8%
1y▲ 20.4%
🏦Market Cap
$885M
Small Cap
📈Revenue Growth (YoY)
66.9%
High Growth
📊Gross Margin
89.4%
High
💵FCF Margin
49.7%
Strong
⚖️P/S Ratio
8.5x
Elevated
Otter Score
72
Strong

Trading Snapshot

Day Range
$17.02 – $17.07
52-Week Range
$13.08 – $21.03
Volume (shares)
275,720
Avg Volume (shares)
—
Shares Outstanding
51.9M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$107M
Last Q Revenue
$21M
P/E Ratio
16.0
P/S Ratio
8.5x
EPS (TTM)
$1.04
Dividend Yield
0.00%
Dilution (1yr)
+7.6%
TBPH logo

THERAVANCE BIOPHARMA INC

TBPH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$107M▲ +66.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
94.9%▲ +128.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▼ −71.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$238M▼ −2109.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
53.1M▲ +7.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$92M▲ +$104M YoY
StockOtter · stockotter.space

About THERAVANCE BIOPHARMA INC

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

News unavailable.